Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
{{output}}
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk-benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate ... ...
